Leading firms’ generic sales growth are stable

Domestic leading drugmakers have enjoyed strong returns, thanks much to increasing market demand. Industry sources expect sales will rise consistently, and Korean drug firms will continue to make a soft landing into the generic markets.

Korean firms have made gains in generic versions of Plavix and Norvasc and is putting out new generic versions of Lipitor, Zocor, and Aricept.

However, cr...